DXCM (DexCom) Deferred Tax: $197 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

DXCM DexCom Inc DXCM
95 GF Score
Price $89.77
GF Value $102.70
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is DexCom Deferred Tax?

DexCom DXCM +0.67% 95 Deferred Tax is $197 Mil as of Jun. 2026. GuruFocus rates DXCM with a GF Score™ of 95/100 and a GF Value™ of $102.70 (Modestly Undervalued). The stock has 3 warning signs investors should review.

Change In Deferred Tax represents future tax liability or asset, resulting from temporary differences between book (accounting) value of assets and liabilities, and their tax value. This arises due to differences between financial accounting for shareholders and tax accounting.

DexCom's change in deferred tax for the three months ended in Jun. 2026 was $-0 Mil. Its change in deferred tax for the trailing twelve months (TTM) ended in Jun. 2026 was $197 Mil.

DexCom Deferred Tax Historical Data

* Premium members only.

The historical data trend for DexCom's Deferred Tax can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

DexCom Deferred Tax Chart

DexCom Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Deferred Tax
Get a 7-Day Free Trial Premium Member Only Premium Member Only 15.80 -21.60 -55.00 -43.80 182.20

DexCom Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Deferred Tax Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -8.90 118.00 78.90 0.30 -0.30
DXCM
95GF Score
DexCom Inc DXCM
Deferred Tax is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

DexCom Deferred Tax Calculation

Change In Deferred Tax represents future tax liability or asset, resulting from temporary differences between book (accounting) value of assets and liabilities, and their tax value. This arises due to differences between financial accounting for shareholders and tax accounting.

Deferred Tax for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $197 Mil.


* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Deferred Tax →
What does a Deferred Tax of $197 Mil mean?
DexCom (DXCM) has a Deferred Tax of $197 Mil as of Jun. 2026. Change in Defered Tax is amount of deferred tax assets or liabilities due to temporary differences in financial and tax accounting. View historical data for DexCom.
Is DexCom's Deferred Tax too high?
DexCom's current Deferred Tax is $197 Mil. Overall, DexCom has a GF Score™ of 95/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does DexCom's Deferred Tax compare to GEHC and STE?
DexCom's Deferred Tax of $197 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Deferred Tax for a Medical Devices & Instruments company?
A good Deferred Tax depends on the Medical Devices & Instruments industry context. However, Deferred Tax should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Deferred Tax mean?
A high Deferred Tax can signal that a stock is expensive relative to its fundamentals. Change in Defered Tax is amount of deferred tax assets or liabilities due to temporary differences in financial and tax accounting. View historical data for DexCom. DexCom's current Deferred Tax is $197 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DexCom stock overvalued right now?
Based on GuruFocus' analysis, DexCom (DXCM) is currently considered Modestly Undervalued. The stock's GF Value™ is $102.70, compared to a current price of $89.77 — trading 12.6% below its estimated fair value. The current Deferred Tax is $197 Mil. DexCom's overall GF Score™ is 95/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Deferred Tax calculated?
Deferred Tax is calculated from a company's financial statements. For DexCom (DXCM), the current Deferred Tax is $197 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is DexCom (DXCM) Overvalued in 2026?

Based on GuruFocus' analysis, DexCom stock appears to be undervalued. The current stock price of $89.77 is trading 12.6% below its estimated GF Value™ of $102.70. GuruFocus considers DexCom to be Modestly Undervalued.

Key valuation signals for DXCM:

  • Deferred Tax: $197 Mil
  • GF Value™: $102.70 vs. price of $89.77 (12.6% below fair value)
  • GF Score™: 95/100 with 3 warning signs

No single metric tells the full story. See the DXCM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

DexCom Business Description

Address 6340 Sequence Drive, San Diego, CA, USA, 92121
DexCom Inc. is a medical device company that develops, manufactures, and sells continuous glucose monitoring (CGM) systems for people with diabetes. Its flagship products include the Dexcom G6 and G7 CGM systems, which use a small wearable sensor and transmitter to measure glucose levels in interstitial fluid and send readings wirelessly to a receiver, smartphone, or smartwatch. The company also offers software platforms such as Dexcom Clarity for data management and Dexcom Share for remote monitoring. Its CGM systems integrate with insulin delivery devices from partners including Insulet and Tandem Diabetes Care to support automated insulin delivery. DexCom sells primarily in the United States, its largest market, as well as in Europe and other international regions. Products reach customers through medical equipment distributors, retail pharmacies, and direct sales channels. Revenue is generated mainly from sensor and transmitter sales, which are recurring because sensors must be replaced regularly.
95GF Score

Get the complete analysis for DXCM

Deferred Tax is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$89.77
Price
$102.70
GF Value